Pseudoephedrine (Protoalkaloid · OTC Decongestant · Meth Precursor · Informational)

Compound	Pseudoephedrine (D-Pseudoephedrine)
Chemical class	Alkaloid — Protoalkaloid (Phenylpropanolamine; stereoisomer of ephedrine)
CAS	90-82-4
Primary source	Ephedra sinica (Ma Huang stems), Ephedra species; also produced synthetically
Key applications	OTC nasal decongestant (Sudafed); controlled substance precursor; informational reference
Claim strength	High (as OTC pharmaceutical decongestant); Informational only
Typical form	OTC pharmaceutical tablet (Sudafed); regulated behind pharmacy counter in US; banned from supplements
Buy from Herbuno	Browse HerbIQ Compound Index →

Name origin: Pseudo- (from Greek, “false”) + ephedrine — indicating its status as a stereoisomer of ephedrine. Pseudoephedrine is the (1S,2S) stereoisomer of ephedrine (1R,2S). The different stereochemistry at C-1 gives pseudoephedrine less CNS penetration and cardiac stimulation than ephedrine, making it a more suitable nasal decongestant. Traditional use: Same as ephedrine — both are alkaloids of Ephedra sinica (Ma Huang). Pseudoephedrine is typically present in slightly lower concentration than ephedrine in Ephedra species. Current regulatory status: Pseudoephedrine is the most widely used nasal decongestant globally — marketed as Sudafed, Clarinase, and numerous OTC combination cold remedies. However, pseudoephedrine is also the primary precursor for illicit methamphetamine synthesis. The US Combat Methamphetamine Epidemic Act (CMEA, 2005) restricted pseudoephedrine OTC sales — requiring behind-the-counter sale with ID and quantity limits. Canada, Australia, and many other countries have similar restrictions. Supplement status: Banned from dietary supplements (same FDA 2004 rule as ephedrine). OTC pharmaceutical use regulated but permitted under CMEA quantity restrictions.

---

Pseudoephedrine — Pharmaceutical and Regulatory Context

Nasal decongestant mechanism (alpha-1 agonism): Pseudoephedrine stimulates α1-adrenergic receptors in nasal mucosa blood vessels, causing vasoconstriction and reducing mucosal oedema (nasal congestion). It also has some β2 activity contributing to bronchodilation. Unlike topical decongestants (oxymetazoline, xylometazoline), which cause rebound congestion (rhinitis medicamentosa) after 3–5 days, oral pseudoephedrine does not produce clinically significant rebound congestion. Multiple meta-analyses confirm significant reduction in nasal congestion from pseudoephedrine versus phenylephrine (the common pharmacy substitute). Claim strength: High (OTC pharmaceutical evidence).

Phenylephrine controversy — why pseudoephedrine matters: Phenylephrine is the OTC decongestant most commonly found on pharmacy shelves in the US (since pseudoephedrine was moved behind the counter). However, the FDA advisory committee in 2023 concluded that oral phenylephrine at OTC doses is NOT effective as a nasal decongestant — based on pharmacokinetic data showing 38% first-pass metabolism and inadequate plasma levels at 10 mg oral dose. This FDA conclusion creates renewed interest in pseudoephedrine as the only effective OTC oral decongestant with robust evidence. Pharmaceutical relevance: High.

Methamphetamine precursor — regulatory context: Pseudoephedrine is the primary precursor for methamphetamine synthesis (pseudoephedrine → meth via reduction of the β-hydroxyl group). The CMEA (2005) restrictions on pseudoephedrine purchase significantly reduced domestic methamphetamine production in the US initially. However, methamphetamine production subsequently shifted to Mexico using precursor chemicals unavailable under CMEA, reducing the real-world impact of the US restrictions. Regulatory reference.

---

Frequently Asked Questions — Pseudoephedrine

Why is pseudoephedrine better than phenylephrine as a decongestant?
Pseudoephedrine has approximately 90% oral bioavailability and achieves therapeutic plasma concentrations at 60 mg oral dose (the standard decongestant dose). Phenylephrine at 10 mg oral dose (the OTC dose) achieves only ~1% systemic availability due to extensive first-pass intestinal and hepatic metabolism — the systemic concentration is insufficient for nasal decongestant effect. Intranasal phenylephrine (topical) is effective; oral phenylephrine is not, based on the 2023 FDA advisory committee conclusion.

How do CMEA quantity limits work in the US?
US consumers can purchase maximum 3.6 g pseudoephedrine per day and 9 g per 30-day period. Purchase requires showing government-issued photo ID, which is recorded electronically in state tracking systems. Individual pharmacies may limit sales based on the state electronic tracking system flags. Bulk purchase for legitimate commercial use (compounding pharmacies) requires DEA registration and documentation.

Is pseudoephedrine safe in cardiovascular disease?
Pseudoephedrine raises systolic blood pressure modestly (~2–4 mmHg) and heart rate in normotensive individuals at standard 60 mg doses. In hypertensive patients, blood pressure increases may be clinically significant. Standard OTC labelling advises people with hypertension, heart disease, thyroid disease, or diabetes to consult a physician before use. At OTC doses (60 mg), the cardiovascular risk in healthy individuals is considered low; in patients with significant cardiovascular disease, medical supervision is appropriate.

Does pseudoephedrine cause addiction or dependence?
At OTC doses for nasal congestion, pseudoephedrine is not considered addictive. It does not produce the euphoria or addiction potential of amphetamines despite the chemical similarity, because it has much lower CNS penetration and weaker dopamine-releasing effects. Some patients use pseudoephedrine in excessive doses for stimulant effects (“poor man’s speed”) but this is not a significant public health concern at the scale of methamphetamine or other stimulant abuse.

Related compounds: Ephedrine, Synephrine, Hordenine, Capsaicin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery